BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase III
CEL-SCI (CVM) Expands Its Global Phase 3 Immunotherapy Head And Neck Cancer Trial Into Centre Hospitalier Universitaire De Quebec In Canada 8/19/2014
Good News For Amgen (AMGN) As Parathyroid Drug AMG 416 Succeeds In Phase 3 Study 8/19/2014
Actavis (ACT) Reports Positive Top-Line Data From Two Ceftazidime-Avibactam Late-Stage Trials 8/19/2014
Amgen (AMGN) Drops After Hours On Failed Phase 3 Multiple Myeloma Trial 8/18/2014
Auspex Pharmaceuticals Completes Enrollment In Phase 3 Registration Clinical Trial Of SD-809 In Chorea Associated With Huntington's Disease 8/18/2014
FDA Accepts CorMedix (CRMD) Pivotal Phase 3 Study Protocol 8/15/2014
Supernus Pharmaceuticals (SUPN) Snags FDA Fast Track Designation For ADHD Drug SPN-810 8/15/2014
AstraZeneca PLC (AZN) Starts Late-Stage Asthma Drug Trial 8/14/2014
Taxus Cardium (CRXM) Announces Biological And Clinical Advances In Angiogenic Gene Therapy For Heart Disease In Journal Of Cardiovascular Pharmacology 8/13/2014
Cardium Therapeutics, Inc. (CXM) Announces Review In Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 8/13/2014
Mologen AG (MOLGF.PK): Preparation And Launch Of New Studies Characterized The First Half-Year 2014 8/13/2014
AstraZeneca PLC (AZN) Gets A Pipeline Boost From Good Phase 3 Gout Drug Results 8/13/2014
Northwest Biotherapeutics (NWBO) Corrects Ongoing False Claims, Phase 3 Dcvax®-L Trial Is Alive And Well 8/13/2014
Novartis AG (NVS) To Tout Heart Failure Data At European Society of Cardiology Congress 2014 8/12/2014
Cempra Initiates Phase 3 Clinical Trial In Patients With Uncomplicated Gonorrhea Infection 8/12/2014
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014
Cortendo AB: First Patient Enrolled Into Normocort Phase 3 SONICS Trial Following A Successful EU Investigator Meeting 8/12/2014
Salix Pharmaceuticals, Ltd. (SLXP) Announces Important Topline Results For Microbiome, Culture & Susceptibility, And Key Secondary Efficacy Results For TARGET 3, Rifaximin IBS-D Repeat Treatment Study 8/12/2014
Opko Health, Inc. Release: Rayaldee Phase 3 Trial Meets Primary Endpoints 8/12/2014
Tolero Pharmaceuticals And Eutropics Pharmaceuticals Announce Data Demonstrating Clinical Utility Of Praedicare Dx In Guiding New Drug Treatment Of CLL Patients 8/12/2014
Evoke Pharma, Inc. Announces Initiation Of A Thorough ECG (QT) Study For EVK-001 8/12/2014
Genmab A/S (GEN.CO) Announces New Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 8/11/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) Provides Updates On Progress Of Phase 3 Firdapse Study In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 8/11/2014
Northwest Biotherapeutics (NWBO) Provides Update About Phase 3 Dcvax®-L Trial For Gbm And "Information Arm" Compassionate Use Patients 8/11/2014
Northwest Biotherapeutics (NWBO) Obtains Approvals For Enhancements Of Phase 3 Trial Of Dcvax®-L For Gbm Brain Cancer 8/11/2014
Avillion Announces Dosing Of First Patients In Phase 3 BFORE Trial To Assess BOSULIF® (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia 8/11/2014
Collegium Pharmaceutical, Inc. Announces Positive Top-Line Data From Phase III Study of Oxycodone DETERx®, Its Abuse-Deterrent, Extended-Release Product For Chronic Pain 8/7/2014
CTI BioPharma Granted Fast Track FDA Status For Pacritinib 8/7/2014
BioDelivery Sciences International (BDSI) Provides Update On Ongoing Phase 3 Pivotal Trial For Clonidine Topical Gel For Painful Diabetic Neuropathy 8/6/2014
New Data Shows High Efficacy For Can-Fite BioPharma (CFBI)'s CF101 In Rheumatoid Arthritis And Psoriasis Patients 8/6/2014
Concordia Healthcare Corp (CXR.TO) Initiates Phase 3 Bile Duct Cancer Trial Using Photodynamic Therapy With PHOTOFRIN® 8/5/2014
Hope Builds For New Novartis AG (NVS) Heart Failure Drug LCZ696 8/5/2014
Amgen (AMGN) Drug Kyprolis Helped Patients Live 8.7 Months Longer In Late-Stage Trial 8/5/2014
XBiotech USA, Inc. Enrolls First Patient In Phase III European Registration Study Using Xilonix™ For Treatment Of Colorectal Cancer 8/4/2014
Mologen AG (MOLGF.PK): First Approvals For Phase III IMPALA Colorectal Cancer Study 8/4/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-SMN Rx In Infants With Spinal Muscular Atrophy 8/1/2014
CEL-SCI (CVM) Achieves Milestone In July With Total Of 232 Patients Enrolled To Date In Its Phase 3 Head And Neck Cancer Trial 8/1/2014
Genmab A/S (GEN.CO), GlaxoSmithKline (GSK)'s Ofatumumab Meets Primary Endpoint In Late-Stage Study 8/1/2014
New Data On Chimerix, Inc. (CMRX)'s brincidofovir Supports Safety And Antiviral Activity Against Multiple Life-Threatening DNA Viruses In Organ Transplant Recipients 7/31/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Publication Of Post-Hoc Analyses Of Lorcaserin Phase 3 Clinical Trial Results In Obesity 7/30/2014
Alkermes plc (ALKS) Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 7/30/2014
Bioniche Life Sciences Inc. (BNC) Announces Submission Of Orphan Drug Designation Application For MCNA In The United States 7/29/2014
Incyte Corporation (INCY)'s Jakafi Fails to Provide RELIEF In Phase 3 Trial 7/28/2014
Celsion Corporation (CLSN) Shows Off Positive ThermoDox® Data In Primary Liver Cancer Patients 7/28/2014
TetraPhase Pharmaceuticals Completes Enrollment Of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections 7/28/2014
Incyte Corporation (INCY) Release: Jakafi® (ruxolitinib) Product Label Expanded To Include Overall Survival Data And Additional Safety And Dosing Information 7/28/2014
Puma Biotechnology (PBYI) Shares Soar On Breast Cancer Drug Results 7/28/2014
Amgen (AMGN), Bayer HealthCare (BAY)'s Nexavar Fails Late-Stage Breast Cancer Study 7/25/2014
Kidney Dialysis Drug Phase 3 Data Boost Keryx Biopharmaceuticals (KERX)'s Hopes For U.S. Approval 7/25/2014
DermaTools Biotech GmbH Release: Clinical Development Of Wound Healing Drug Dermapro® Progressing On Schedule In Europe 7/25/2014
Aerie Pharmaceuticals, Inc. (AERI) Receives Health Canada "No Objection Letter" To Commence Phase 3 Registration Trial Of Rhopressatm In Patients With Glaucoma In Canada 7/24/2014
Bayer HealthCare AG (BAY) Release: Phase 3 Investigational Trial Of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints In Subjects With Papulopustular Rosacea 7/24/2014
Merck & Co., Inc. (MRK) Initiates Phase 3 Study Of Letermovir, An Investigational Antiviral For Prevention Of Cytomegalovirus (CMV) Infection In High-Risk Bone Marrow Transplant Patients 7/24/2014
rEVO Biologics Announces Enrollment Of First Patient In Phase 3 Trial Of Atryn® To Treat Early Onset Preeclampsia (PRESERVE-1) 7/24/2014
Pfizer Inc. (PFE) Backs Out of Funding Puma Biotechnology (PBYI) Cancer Drug Trials 7/24/2014
ViiV Healthcare: HIV Combo Therapy Candidate Fails Phase 3 7/23/2014
Major Advance In UCB Pipeline: Positive Topline Phase 3 Results For brivaracetam In Epilepsy Patients With Partial-Onset Seizures 7/23/2014
CEL-SCI (CVM) Has Been Cleared to Begin Patient Enrollment 7/23/2014
Synta Pharmaceuticals (SNTA) Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML LI-1 Study For Patients With AML And High-Risk MDS 7/22/2014
Nymox Pharmaceutical (NYMX) Announces Positive Efficacy Results In Phase 3 Repeat Injection Trial Of NX-1207 For BPH 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
Antares Pharma, Inc. (ATRS) Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
PSI CRO Launches A Global Phase 3 Rare Disease Trial 7/22/2014
Amgen (AMGN) Thyroid Drug AMG 416 Succeeds In Late Stage Kidney Patient Trial 7/21/2014
Proteon Therapeutics, Inc. Initiates Phase 3 Clinical Study Of PRT-201 In Patients With Chronic Kidney Disease Undergoing Surgical Placement Of An Arteriovenous Fistula For Hemodialysis 7/21/2014
Braeburn Pharmaceuticals Enrolls First Patients In Late-Stage Clinical Study Of Probuphine® For Opioid Dependence 7/21/2014
Dipexium Pharmaceuticals (DPRX) Initiates Second Of Two Pivotal Phase 3 Clinical Trials Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers 7/21/2014
InterMune, Inc. (ITMN) Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone 7/18/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 7/18/2014
Regeneron Pharmaceuticals, Inc. (REGN) Release: Two-Year Results From Phase 3 VIVID-DME Trial Of EYLEA® (aflibercept) Injection For The Treatment Of Diabetic Macular Edema Show Sustained Improvement In Vision 7/18/2014
Agile Therapeutics, Inc. Announces Allowance Of Additional Patent Claims For Skinfusion® 7/18/2014
Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial For SD-809 In Tardive Dyskinesia 7/17/2014
CEL-SCI (CVM) Expands Its Phase 3 Head And Neck Cancer Trial Into Sri Lanka 7/17/2014
Dipexium Pharmaceuticals (DPRX) Initiates Pivotal Phase 3 Clinical Trial Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers 7/17/2014
New England Journal Of Medicine Publishes Ipsen (IPN.PA)’s Somatuline® CLARINET® Phase III Results In Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors 7/17/2014
TauRx Therapeutics Achieves Enrollment Target In The First Of Its Two Phase III Clinical Trials Of LMTX™ In Alzheimer's Disease 7/17/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Begin Pivotal Phase 3 Trial For Triple Combination Treatment 7/16/2014
Boehringer Ingelheim Corporation's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation 7/16/2014
Pfizer Inc. (PFE) Hemophilia B Treatment Regimen Meets Endpoint In Phase 3 Trial 7/16/2014
Rigel Pharmaceuticals, Inc. (RIGL) Initiates Phase 3 Studies Of Fostamatinib In ITP 7/16/2014
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy) 7/16/2014
AVANIR Pharmaceuticals (AVNR) Announces Presentation Of Positive Early Results From Prism II Study 7/16/2014
Exelixis, Inc. (EXEL) And Genentech (RHHBY)'s Melanoma Combination Drug Meets Main Goal In Phase 3 Study 7/15/2014
ZS Pharma (ZSPH) Completes Patient Enrollment In ZS004, Its Second Phase 3 Study Of ZS-9 In Patients With Hyperkalemia 7/15/2014
Eli Lilly and Company (LLY) Release: New Data Shows Cognitive Impairment Precedes And Predicts Subsequent Functional Impairment In Patients With Mild Alzheimer's Disease 7/15/2014
Nymox Pharmaceutical (NYMX) Announces Completion Of Enrollment For Second BPH Re-Injection Study 7/15/2014
Aerie Pharmaceuticals, Inc. (AERI) Initiates Phase 3 Registration Trials of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 7/15/2014
Neos Therapeutics Announces Positive Phase 3 Study Results For Its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) In ADHD Patients 7/15/2014
FDA Green Lights Starpharma Holdings Ltd's VivaGel Trial Design 7/14/2014
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Orphan Drug Designations In Europe For The Treatment Of Invasive Mold Infections 7/14/2014
Alcobra (ADHD) Completes Patient Recruitment In Phase 3 Clinical Trial Of MDX In Adult ADHD 7/14/2014
Synergy Pharmaceuticals Reaches Halfway Mark For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Novartis AG (NVS)'s New Drug Secukinumab Shows Promise In Two Pivotal Phase 3 Trials 7/11/2014
FDA Places Regado Biosciences, Inc. (RGDO)'s Phase 3 Revolixys Trial On Clinical Hold 7/11/2014
Celgene (CELG)'s OTEZLA® Misses Mark In Phase 3 Spinal Arthritis Study 7/10/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
TransTech Pharma, Inc. Announces Agreement With FDA On Special Protocol Assessment For TTP488 Phase 3 Trial In Patients With Mild Alzheimer’s Disease 7/10/2014
SillaJen Lead Product Pexa-Vec Featured In "Nature Reviews Cancer" Article Summarizing The Potential Of Oncolytic Immunotherapy 7/10/2014
Oxygen Biotherapeutics, Inc. (OXBT) Release: Recent Scientific Publications Highlight Potential Benefits Of Levosimendan In Cardiac Surgery And Additional Critical Care Conditions 7/9/2014
La Jolla Pharmaceutical Company (LJPC) Announces Planned Initiation Of Phase 3 Registration Program For LJPC-501 In Resistant Hypotension 7/9/2014
Vital Therapies, Inc. (VTI) (VTL) Reports On Clinical Trial Progress And EU Regulatory Advice 7/9/2014
San Diego's Otonomy, Inc. Touts Positive Data From Two Phase 3 Trials Of Auripro™ 7/8/2014
CEL-SCI (CVM) Receives Regulatory Clearance To Expand CEL-SCI’S Phase 3 Head And Neck Cancer Trial Into Austria 7/8/2014
Eli Lilly and Company (LLY) To Showcase Data From Its Alzheimer's Disease Portfolio At The Alzheimer's Association International Conference 2014 (AAIC 2014) 7/8/2014
Endo International plc (ENDP), BioDelivery Sciences International (BDSI) Painkiller BEMA® Buprenorphine Effective In Phase 3 Study 7/7/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX)’s Strategic Partner G-Treebnt Preparing For Phase 3 Dry Eye Trials In Asia With RGN-259 7/7/2014
Regado Biosciences, Inc. (RGDO) Shares Nearly Halved After Announcing Trial Review; Stock Down -58.43% At Market Close (July 3, 2014) 7/7/2014
Salix Pharmaceuticals, Ltd. (SLXP) Surges On Encouraging Phase 3 Results For Rifaximin; Stock Up +13.51% At Market Close (July 1, 2014) 7/2/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO) Leukemia Drug Ofatumumab Fails To Meet Main Trial Goal 7/2/2014
CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis 7/1/2014
Synageva BioPharma (GEVA) Details Positive Phase 3 Data Of Sebelipase Alfa 7/1/2014
CEL-SCI (CVM) Reports 93 Percent Increase In Sequential Quarterly Patient Enrollment In Its Phase 3 Head And Neck Cancer Trial 7/1/2014
Specialty Vaccine Company PaxVax, Inc. Announces Positive Efficacy Results For Phase 3 Cholera Challenge Study 7/1/2014
GlycoMimetics, Inc. (GLYC) Announces Agreement With FDA On Special Protocol Assessment For Phase 3 Clinical Trial Of Rivipansel (GMI-1070) 7/1/2014
Taiho Oncology's Colorectal Cancer Drug TAS-102 Improves Overrall Survival In Phase 3 Trial 6/30/2014
Merck & Co., Inc. (MRK)'s Pediatric Anti-Vomiting Drug Effective In Phase 3 Trial 6/30/2014
Amicus Therapeutics, Inc. (FOLD) Provides Updates And Final Analysis Plan For Phase 3 Fabry Monotherapy Study 012 6/30/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014
PTC Therapeutics, Inc. (PTCT) Initiates Confirmatory Phase 3 Clinical Trial Of Translarna™ (Ataluren) In Patients With Nonsense Mutation Cystic Fibrosis (nmCF) 6/30/2014
Alimera Sciences (ALIM)' ILUVIEN® Receives Positive Outcome Of Repeat-Use Procedure For 10 Additional European Countries 6/30/2014
Icon Bioscience Announces Early Completion Of Patient Enrollment In Its Phase 3 Study Of IBI-10090; Drug Addresses Market Need For Long-Acting Treatment Of Inflammation Post Cataract Surgery 6/30/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/27/2014
H. Lundbeck A/S (LUN.CO)'s Late Stage Trials For Stroke Failed To Meet Primary Endpoint 6/27/2014
CRO Health Decisions, Evofem Lock Database In Largest Contraceptive Trial Of Its Type 6/27/2014
Boehringer Ingelheim Corporation's Investigational Antidote For Pradaxa® Grabs FDA Breakthrough Therapy Designation 6/26/2014
AbbVie (ABBV) Announces Initiation Of Pivotal Phase 3 Study Of Veliparib (ABT-888) In Patients With Advanced Breast Cancer 6/26/2014
Merrimack Pharmaceuticals Inc. (MACK) Presents Data From Phase 3 NAPOLI-1 Study At The ESMO 16th World Congress On Gastrointestinal Cancer 6/26/2014
BioDelivery Sciences International (BDSI) Announces Completion Of Patient Enrollment In Its Initial Phase 3 Trial Of Clonidine Topical Gel For Painful Diabetic Neuropathy 6/26/2014
ZS Pharma (ZSPH) Announces Start Of Enrollment Of Phase 3 Long-Term Maintenance Study Of ZS-9 In Patients With Hyperkalemia 6/26/2014
Bristol-Myers Squibb Company (BMY) Stops Skin Study On Positive Phase 3 Data 6/26/2014
Vertex Pharmaceuticals (MA) (VRTX) Rockets As Cystic Fibrosis Combo Succeeds In Two Late Stage Trials 6/25/2014
FDA Requests More Data For Basilea Pharmaceutica (BSLN.SW)'s Pneumonia Drug Ceftobiprole; Stock Drops -8.15% At Market Close (June 25, 2014) 6/25/2014
Orexo AB (ORXOF) Release: Top-Line Data From A Phase 3 Clinical Trial Demonstrates That Zubsolv® Is As Effective As Suboxone® Film In The Treatment Of Opioid Dependence 6/25/2014
Ligand Pharmaceuticals Inc. (LGND) Partner GlaxoSmithKline (GSK) Announces The Start Of A Phase 3 Study With Eltrombopag In Patients With Myelodysplastic Syndromes 6/25/2014
Due To Positive Feedback, Ampio Pharmaceuticals, Inc. (AMPE) Closes Enrollment Of OptimEyes Study, Will Present Data To FDA For Guidance 6/25/2014
Cardium Therapeutics, Inc. (CXM) Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy Of Generx® Angiogenic Gene Therapy For Myocardial Ischemia Due To Coronary Artery Disease At The 2014 Biotechnology Industry Organization (BIO) International Convention 6/24/2014
Taxus Cardium (CRXM) Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy Of Generx® Angiogenic Gene Therapy For Myocardial Ischemia Due To Coronary Artery Disease At The 2014 Biotechnology Industry Organization (BIO) International Convention 6/24/2014
AVANIR Pharmaceuticals (AVNR) Announces Three Data Presentations Related To AVP-825 For The Acute Treatment Of Migraine At The American Headache Society Annual Meeting 6/24/2014
Burzynski Research Institute Announces Lifting Of The FDA Partial Clinical Hold - Phase 3 Clinical Study Agreed Upon 6/24/2014
CorMedix (CRMD) Finalizes Pivotal Phase 3 Study Protocol For FDA 6/24/2014
Auspex Pharmaceuticals Announces Data From Interim Analysis Of ARC-HD Switch Trial Demonstrating Clinical Activity Of SD-809 6/24/2014
Cystic Fibrosis Foundation Applauds Successful Phase 3 Results Of Ivacaftor (Kalydeco™) And Lumacaftor (VX-809) Drug Combination For People With Two Copies Of F508del Mutation Of Cystic Fibrosis 6/24/2014
Positive New Phase 3a Data On Novo Nordisk A/S (NVO)'s Liraglutide 6/23/2014
The European Medicines Agency And FDA Grant Orphan Drug Designation To PHARNEXT's PXT-3003 For The Treatment Of Charcot-Marie-Tooth Disease Type 1A 6/23/2014
Regado Biosciences, Inc. (RGDO)' REG2 Demonstrates Dose And Concentration-Dependent Suppression Of Thrombin Generation 6/23/2014
Orexo AB (ORXOF) Release: Positive Top-Line Results From Two Phase 3 Clinical Trials That Assessed Zubsolv® For Induction Of Buprenorphine Maintenance Therapy 6/23/2014
Clarus Therapeutics Presents Phase 3 Data For REXTORO® For Men With Hypogonadism 6/23/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients 6/23/2014
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of Chs-0214 (Investigational Etanercept Biosimilar) In Rheumatoid Arthritis 6/23/2014
Aradigm Corporation (ARDM) Announces The Dosing Of The First Patient In Phase III Study Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 6/23/2014
NephroGenex (NRX) Initiates Pivotal Phase 3 Study With Novel Treatment To Slow Progression Of Diabetic Kidney Disease 6/20/2014
Boehringer Ingelheim (Canada) Ltd. Release: Study Findings Show Tiotropium Respimat®* Well-Tolerated And Effective In Japanese Patients With Symptomatic Asthma 6/19/2014
Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye 6/19/2014
Two-Year Results From Pfizer Inc. (PFE)’s XELJANZ® (Tofacitinib Citrate) ORAL Start Study Published In The New England Journal of Medicine 6/19/2014
Provectus Biopharmaceuticals Inc. To Hold Conference Call Today To Detail Outline Of Phase 3 Clinical Trial Of PV-10 In Melanoma Treatment 6/19/2014
AstraZeneca PLC (AZN) Release: Data Published In The New England Journal of Medicine Demonstrate Naloxegol Improved Opioid-Induced Constipation In Chronic Pain Patients 6/19/2014
Successful Phase 3 Results For Alkermes plc (ALKS)'s Schizophrenia Drug Aripiprazole Lauroxil 6/19/2014
TetraPhase Pharmaceuticals Completes Enrollment in Lead-in Portion of IGNITE 2 Eravacycline Phase 3 Clinical Trial in cUTI 6/19/2014
Actelion Ltd. (ALIOF.PK) Soars As Heart-Lung Drug Selexipag Meets Main Goal In Late-Stage Study 6/18/2014
Intarcia Therapeutics, Inc.'s Once-A-Year Diabetes Drug ITCA 650 Impresses In Phase 3 Trial 6/17/2014
Biogen Idec, Inc. (Massachusetts) (BIIB), AbbVie (ABBV)'s Once-A-Month Drug Daclizumab Slows Multiple Sclerosis Episodes, Safety Issues Reoccur 6/17/2014
Eli Lilly and Company (LLY) Announces Detailed Results From Two Phase III Studies Testing Both Doses Of Dulaglutide Vs. Insulin Glargine 6/17/2014
Eli Lilly and Company (LLY)'s Once-Weekly Dulaglutide Shows Similar Reductions In Average Blood Glucose Levels As Once-Daily Liraglutide In Head-to-Head Trial 6/17/2014
Merrimack Pharmaceuticals Inc. (MACK) Announces Oral Presentation Of Additional Data Results In Phase 3 NAPOLI-1 Study At The ESMO 16th World Congress On Gastrointestinal Cancer 6/17/2014
Nymox Pharmaceutical (NYMX) Reports Positive Update On Nerve Sparing And Sexual Function Preservation In Men Treated With NX-1207 6/17/2014
Janssen Research & Development Release: New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose In Older Patients With Type 2 Diabetes Inadequately Controlled On Other Therapies 6/17/2014
Upsher-Smith Laboratories Release: Qudexy™ XR (Topiramate) Extended-Release Capsules Phase 3 Data Published In Epilepsia 6/17/2014
AmVac AG Initiates Phase III Trial With Its Lead Vaccine Gynevac For The Treatment Of Bacterial Vaginosis 6/17/2014
AbbVie (ABBV)'s Chronic Hepatitis C Regimen Gets Priority Review From The FDA 6/16/2014
Novo Nordisk A/S (NVO)'s Big-Selling Diabetes Drug Victoza Appears Effective For Weight Loss 6/16/2014
Sanofi (France) (SAN.PA) Toujeo Shows Great Promise As Lantus Successor 6/16/2014
Gilead Sciences, Inc. (GILD) Announces Phase 3 Data Showing That The Fixed-Dose Combination Of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients With Chronic Hepatitis C In Japan 6/16/2014
Celgene International Sárl (CELG) Release: Retrospective Analysis Of Overall Survival Adjusting For Patient Crossover In Phase III Study Of POMALYST®/IMNOVID® (Pomalidomide) In Previously Treated Multiple Myeloma Presented At EHA 6/16/2014
Celgene International Sárl (CELG) Release: Results From Phase III Study (AML-001) Of VIDAZA® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At European Hematology Association 6/16/2014
Eli Lilly and Company (LLY) Release: Type 2 Diabetes: Investigational Compound empagliflozin As An Add-On Therapy Significantly Reduced Blood Glucose And Body Weight In Two Newly Presented Phase 3 Trials 6/16/2014
Studies Show Investigational New Insulin Glargine Product From Eli Lilly and Company (LLY) And Boehringer Ingelheim Corporation Similar Safety And Efficacy Profile To Lantus® 6/16/2014
Novo Nordisk A/S (NVO) Release: Phase 3a Data Showed Liraglutide 3 Mg Demonstrated Significantly Greater Weight Loss Compared To Placebo In Adults With Obesity And Type 2 Diabetes 6/16/2014
Intarcia Therapeutics, Inc. Presents Interim Phase 3 Data At American Diabetes Association Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar In Patients With Very Poorly Controlled Diabetes 6/16/2014
Mast Therapeutics (MSTX) Initiates Sub-Study Within Phase 3 EPIC Trial 6/16/2014
Novo Nordisk A/S (NVO) Combination Diabetes Drug IDegLira Effective After 1 Year Study 6/16/2014
Eli Lilly and Company (LLY)'s Once-Weekly Dulaglutide Shows Similar Reductions In Average Blood Glucose Levels As Once-Daily Liraglutide In Head-to-Head Trial 6/16/2014
Eisai Inc. (ESALF.PK)'s Antiepileptic Drug Perampanel Meets Primary Endpoint In Phase 3 Study 6/16/2014
Eli Lilly and Company (LLY) Release: Type 2 Diabetes: Jardiance® (Empagliflozin) As An Add-On Therapy Significantly Reduced Blood Glucose And Body Weight In Two Newly Presented Phase 3 Trials 6/16/2014
Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Tout Positive Phase 3 Data For Rheumatoid Drug Sarilumab 6/13/2014
Ligand Pharmaceuticals Inc. (LGND) Partner GlaxoSmithKline (GSK)'s Phase 3 PETIT2 Study Meets Primary Endpoint 6/13/2014
US FDA Advisory Committee Recommends No Cardiovascular Outcomes Trial For Peripherally-Acting Mu-Opioid Receptor Antagonist (Pamora) Class Including Movantik 6/13/2014
Eli Lilly and Company (LLY)'s Cyramza Misses Primary Endpoint In Critical Phase 3 Study 6/12/2014
Medimetriks Pharmaceuticals, Inc. Announces That The Second Phase 3 Study For Ozenoxacin Has Been Initiated By Ferrer 6/12/2014
GlaxoSmithKline (GSK) And Theravance, Inc. (THRX) Announce Positive Data From Two Studies Evaluating The Efficacy And Safety Of Incruse® Ellipta® When Added To Relvar®/Breo® Ellipta(®) In Patients With COPD 6/12/2014
Ambit Biosciences Announces Presentation Of Data From Clinical Investigations Of Quizartinib At The 19th Congress Of The European Hematology Association 6/12/2014
Iroko Pharmaceuticals Takes Low Dose Approach To Osteoarthritis Pain Meds To Avoid Adverse Events In Phase 3 Study 6/12/2014
Nymox Pharmaceutical (NYMX) Reports Positive New Safety Study Data For Phase 3 BPH Drug 6/12/2014
Cardium Therapeutics, Inc. (CXM) To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 Biotechnology Industry Organization (BIO) International Convention 6/12/2014
Vertex Pharmaceuticals (MA) (VRTX) Announces Presentation Of New KALYDECO™ (Ivacaftor) Data At European Cystic Fibrosis Society Conference 6/12/2014
Iroko Pharmaceuticals Release: SoluMatrix® Meloxicam Demonstrates Significant Efficacy At 30 Percent Lower Doses In The Treatment Of Osteoarthritis 6/12/2014
Phase 3 Data Demonstrate Comparability Of Epirus’ BOW015 To Remicade® For Treatment Of Rheumatoid Arthritis 6/12/2014
All Eyes Are On AstraZeneca PLC (AZN) As Its Diabetes Drugs Go Under The Spotlight At Major Scientific Meeting 6/12/2014